Datasea Files DUNS to Advance FDA Registration of Acoustic BCI with 4 Core Capabilities
DTSS•Datasea Intelligent Technology has submitted its DUNS application as part of preparatory steps toward U.S. FDA establishment registration and device listing for its acoustic brain-computer interface product. The non-invasive BCI integrates acoustic stimulation, bone-conduction neuromodulation, EEG acquisition and AI health management for neurological applications.
1. Regulatory Preparations for U.S. FDA Listing
The company has submitted its Dun & Bradstreet DUNS application as a key administrative step toward U.S. FDA establishment registration and device listing for its acoustic BCI product. It plans to prepare and submit documentation on establishment registration, device listing, technical specifications and product testing in line with FDA requirements.
2. Acoustic BCI Product Capabilities and Applications
The non-invasive BCI integrates four core capabilities—acoustic stimulation, bone-conduction neuromodulation, EEG signal acquisition and AI-assisted health management—for applications in brain health management, rehabilitation support, cognitive monitoring, sleep optimization and emotional regulation.
3. Risks, Timelines and Next Steps
FDA clearance is not yet obtained and review timelines, regulatory requirements and outcomes remain uncertain. Datasea will update on material progress and follow a systematic compliance strategy, but investors should note that registration and listing steps do not imply approval for commercial distribution.
